Hesco Class 1 new drugs are about to be approved! The market for 10 billion narcotics is cracking

Recently, Hesco's class 1 new drug HSK3486 emulsion injection application entered the approval status, will soon be approved for market.
it is understood that the product is intended for surgical full hemp induction, endoscopic sedatives/ anesthesia, ICU sedation and other adaptive disorders, this is expected to be approved by the company in 2019 declared the adaptation, digestive endoscopy diagnosis and treatment of sedation and/or anesthesia (acceptance number: CXHS190020).
figure 1: HSK3486 emulsion registration progress source: NMPA official website according to the Haisco announcement, HSK3486 emulsion is the company developed a new venous anesthesiology drug with independent intellectual property rights, intended for surgery full hemp induction, endoscopic sedation / anesthesia, ICU sedation and other indications, drug registration classified as chemical drugs 1 class.
HSK3486 obtained the Drug Clinical Trial Approval issued by NMPA in January 2016 to initiate a clinical trial of "Digestive endoscopic diagnosis and treatment of sedation and/or anesthesia" adaptation, and the application for the new drug was accepted in July 2019 (acceptance number: CXH) S1900020), which was included in the priority review in August of the same year, and in January 2020 the NMPA accepted the application for a new drug for the "general anaesthetic induction" of the product (acceptance number: CXHS2000001), which was included in the priority review in February of the same year.
, the product's "full hemp maintenance" adaptive clinical application has been approved, "sedative during intensive care" adaptive clinical application in the review and approval.
Figure 2: Sales of narcotic drugs Source: Minet China's public medical institutions terminal competition pattern Minet data show that in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal nervous system drug market, the sales volume of narcotic drugs has exceeded 16 billion yuan, 2018-2019 growth rate remained at more than 10%, 2020 first half affected by the epidemic patients reduced frequency of surgery, growth rate decreased by 15%.
Table 1:2020 So far approved for the market of narcotic drug products Source: MED2.0 China Drug Review Database 2020 to date, narcotics in the 10 billion market has been approved for market, of which only 1 new class of drugs Two (Hengrui announced on January 3, 2020 that the injection of toluene sulfonate remathrame was approved for the market), if Hesco's HSK3486 emulsion was successfully approved, it is expected to become the third new class 1 drug to be marketed this year.
source: NMPA official website, MiNet database